Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 272 results found since Jan 2013.
Herpes zoster-prevention, diagnosis, and treatment
CONCLUSION: Implementation of the current recommendations for the prevention, diagnosis and treatment of HZ and PHN is important to reduce the high burden of disease and improve quality of life of the patients.PMID:35477786 | DOI:10.1007/s00105-022-04992-9
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - April 28, 2022 Category: Dermatology Authors: Ricardo Niklas Werner Kamran Ghoreschi Source Type: research
Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination
Hum Vaccin Immunother. 2022 Apr 1:1-11. doi: 10.1080/21645515.2022.2040328. Online ahead of print.ABSTRACTPLAIN LANGUAGE SUMMARYWhat is the context? Herpes zoster or shingles and its complications such as postherpetic neuralgia - a painful condition that affects the nerve fibers and skin - may lead to complex pain that can be addressed using opioids in some patients.The recombinant zoster vaccine (RZV) vaccine prevents shingles and, therefore, may reduce the use of opioids and the negative health outcomes and costs associated with it.What is new? In this retrospective medical claims study, including patients between 2012 a...
Source: Herpes - April 1, 2022 Category: Infectious Diseases Authors: Jean-Etienne Poirrier Jessica K DeMartino Saurabh Nagar Justin Carrico Katherine Hicks Juliana Meyers Jeffrey Stoddard Source Type: research
Serial Thoracic Transforaminal Epidural Steroid Injections for Post-herpetic Neuralgia: A Case Report
Cureus. 2022 Feb 1;14(2):e21808. doi: 10.7759/cureus.21808. eCollection 2022 Feb.ABSTRACTThe chronic neuropathic pain of post-herpetic neuralgia (PHN) often persists for months or years after the acute herpes zoster (shingles) episode, may be severe and intractable, and can severely impact the overall quality of life. Antivirals, analgesics, and nerve blocks can effectively shorten the course of shingles and may help to prevent PHN. Although vaccination effectively prevents shingles and PHN, current therapies may be ineffective, and pain management can be challenging when PHN occurs. A 78-year-old female with severe PHN pa...
Source: Herpes - March 7, 2022 Category: Infectious Diseases Authors: Bao N Dinh HuyKien Le John Dinh Joseph Mouhanna Marcos A Sanchez-Gonzalez Source Type: research
Herpes zoster: A Review of Clinical Manifestations and Management
The objective of this review is to discuss current updates related to clinical presentations, complications, and management of HZ.PMID:35215786 | PMC:PMC8876683 | DOI:10.3390/v14020192
Source: Herpes - February 26, 2022 Category: Infectious Diseases Authors: Anant Patil Mohamad Goldust Uwe Wollina Source Type: research
Viruses, Vol. 14, Pages 192: Herpes zoster: A Review of Clinical Manifestations and Management
The objective of this review is to discuss current updates related to clinical presentations, complications, and management of HZ.
Source: Viruses - January 19, 2022 Category: Virology Authors: Patil Goldust Wollina Tags: Review Source Type: research
Healing of Severe Herpes Zoster Ophthalmicus Within a Few Days: An Autobiographical Case Report
Cureus. 2021 Dec 9;13(12):e20303. doi: 10.7759/cureus.20303. eCollection 2021 Dec.ABSTRACTHerpes zoster (shingles) is caused by the herpes zoster virus and is characterized by pain and unilateral vesicular rash that typically affects one dermatome. Symptoms tend to resolve over 10-15 days. This case report describes the 75-year-old author's herpes zoster ophthalmicus (HZO) accompanied by severe orbital edema. The upper eyelid and the proximal nasal area were also affected. The author felt an intermittent throbbing pain in more than three dermatomes including the frontal, orbital, temporal, and occipital/nuchal areas. Since...
Source: Herpes - January 13, 2022 Category: Infectious Diseases Authors: Tibor Bakacs Source Type: research
Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
Ther Adv Vaccines Immunother. 2021 Nov 30;9:25151355211057479. doi: 10.1177/25151355211057479. eCollection 2021.ABSTRACTAn adjuvanted recombinant zoster vaccine (RZV) is licensed for the prevention of herpes zoster. This paper reviews its safety and reactogenicity. A pooled analysis of two pivotal randomized Phase-3 trials (NCT01165177, NCT01165229) in adults ?50 years found that more solicited adverse events (AEs) were reported with RZV than placebo. Injection site pain was the most common solicited AE (RZV: 78.0% participants; placebo: 10.9%). Grade-3 pain occurred in 6.4% of RZV and 0.3% of placebo recipients. Myalgia, ...
Source: Herpes - January 10, 2022 Category: Infectious Diseases Authors: Joseph Fiore Maribel Miranda Co-van der Mee Andr és Maldonado Lisa Glasser Phil Watson Source Type: research
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
